profit from every CHF 100 of sales.
CHF 0CHF 100
Sandoz Group
CHF 84.60-2.65% today
+47.3% in 1 year
1-year low CHF 57.221-year high CHF 86.90
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay CHF 47.78 for every CHF 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sandoz Group sold, what it kept, and what it did with the cash.
Sales went from $9.31 billion in 2022 to $11.2 billion in 2025, with $914 million of profit last year.
SalesProfit
Sandoz Group handed back 39% of the cash it generated last year.
$315M
Free cash flow 2025$810M
Bought back its own shares$0
Paid as dividends$315M
Cash vs. debt$1.7B vs. $5.7B
Sandoz Group vs. similar companies
Sandoz Group grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Sandoz Group | 47.8× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Sandoz Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 9,306 | 9,979 | 10,384 | 11,157 | |
| 4,378 | 4,564 | 4,926 | 5,284 | |
| 1,239 | 375 | 307 | 1,425 | |
| 1,683 | 857 | 742 | 1,972 | |
| 848 | 77 | 0 | 914 | |
| 1.97 | 0.18 | 0.00 | 2.09 | |
| 47.0% | 45.7% | 47.4% | 47.4% | |
| 13.3% | 3.8% | 3.0% | 12.8% | |
| 9.1% | 0.8% | 0.0% | 8.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 17,557 | 19,430 | 19,907 | 22,032 |
| Cash | 74 | 1,109 | 1,191 | 1,739 |
| Total debt | 333 | 4,553 | 4,853 | 5,683 |
| Total liabilities | 8,797 | 10,776 | 11,743 | 12,647 |
| 8,748 | 8,645 | 8,163 | 9,384 | |
| 431 | 431 | 434 | 437 | |
| 11.1% | 2.1% | 1.6% | 8.1% | |
| 9.7% | 0.9% | 0.0% | 9.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,223 | 362 | 656 | 1,594 | |
| 427 | 625 | 596 | 784 | |
| 796 | -263 | 60 | 810 | |
| Dividends paid | – | – | 215 | 315 |
| – | 0 | 12 | 0 | |
| 0 | 25 | 88 | 102 |
Valuation
- 47.8×
- –
- 23.50
- 4.7×
- 3.9×
- 53.9×
- 24.1×
- 1.9%
- 2.1%
- 0.7%
Profitability
- 47.4%
- 12.8%
- 8.2%
- –
- 8.1%
- 5.7%
- –
- –
- –
- –
Growth
- +6.2%
- +2.0%
- –
- –
- +0.4%
Financial health
- 2.0×
- 0.61
- –
- 6.5×
- 1.18
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 40%of 963
Top 43%of 894
Bottom 25%of 632
Bottom 34%of 908
Top 46%of 991
0.7%of the share price, paid each year
On $1,000 invested$7a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
34.5% of its profit
Room to growStretchedMore than it earns: 38.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
17No pass
Philip Fisher
32No pass
Peter Lynch
19No pass
Joel Greenblatt
6No pass
Charlie Munger
26No pass
Terry Smith
25No pass
Questions about Sandoz Group
Is Sandoz Group a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sandoz Group AI analysis
What does Sandoz Group do?
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. It is in Drug Manufacturers - Specialty & Generic, based in Basel, Switzerland, with 22,356 employees.
Does Sandoz Group pay a dividend?
Yes. At today's price the dividend is 0.7% a year, about 34% of its yearly profit. In 2025 it paid out CHF 315 million in dividends.
Is Sandoz Group stock halal?
Yes. Sandoz Group passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Sandoz Group stock done over the past year?
Up 47.3% over the past twelve months, to CHF 84.60. It traded between CHF 57.22 and CHF 86.90 and is 2.6% below its high.
Who are Sandoz Group's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Sandoz Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.